Table 2. Individual patient... | American Society of Hematology

Table 2.

Individual patient characteristics and clinical response details

Patient no.	FLT3 mutation	Age, y/sex	FAB	WCC, × 10⁹/L	Karyotype	Dose, mg	Best response	Details of response
1	WT	73/F	M2	12.2	Normal	80*	NR	—
2	WT	75/M	M2	8.3	Normal	80	NR	—
3	WT	75/M	M6	0.8	Normal	80	NR	—
4	WT	71/M	M1	2.8	Normal	80	NR	—
5	1836 del	72/M	M6	1.9	Normal	80	HR	Delayed PB response (d 104), transfusion independent†
6	WT	69/F	M1	13.8	add(X)(q2)	80	2 × BMR	98% → 24% BM blasts (60 mg), 50% → 21% BM blasts (80 mg)
7	WT	73/M	NA	1.3	Complex	80	NR	—
8	ITD; 30 bp	67/F	M0	3.3	Normal	60	NR	—
9	WT	81/M	M2	9.3	-Y	60	NR	—
10	WT	78/M	M4	19.8	Normal	80	NR	—
11	WT	72/M	M1	3.1	+8	80	NR	—
12	WT	78/F	M4	23.5	-7, +8	60*	NA‡	—
13	WT	80/M	M4	11.4	+11	80	NR	—
14	WT	70/M	NA	3.4	Normal	60	PD	—
15	ITD; 33 bp	74/F	M1	140.7	Normal	60*	HR	Cleared PB blasts (60 mg)
16	WT	82/F	M1	1.2	t(15;21)	60	NA‡	—
17	WT	72/F	NA	1.0	Normal	80	BMR	80% → 30% BM blasts (60 mg), delayed PB response (d 123), transfusion independent†
18	WT	70/F	M1	1.4	inv(8)	80	NR	—
19	D835Y	74/M	M0	42.4	Normal	80*	HR	Cleared PB blasts (60 mg), transfusion independent
20	WT	68/M	M6	1.9	Complex	60	NR	—
21	WT	75/F	M2	1.6	Normal	80	NR	—
22	WT	75/F	M1	6.1	t(8;21)§	80	NR	—
23	WT	73/M	M5	3.3	Normal§	80	BMR	31% → 10% BM blasts (60 mg)
24	WT	73/M	M4	15.1	Normal§	60	PD	—
25	835-837∥	69/F	M4	31.5	Normal	60*	PD	—
26	WT	70/M	M2	1.9	del(9), +11	80	BMR	90% → 45% BM blasts (60 mg)
27	WT	70/F	M4	10.5	+iso(4)×2	60	PD	—
28	WT	80/F	M2	8.0	del(5q)§	80	BMR	22% → 4% BM blasts (60 mg)
29	WT	74/M	M2	7.0	Complex	60	PD	—

Patient no.	FLT3 mutation	Age, y/sex	FAB	WCC, × 10⁹/L	Karyotype	Dose, mg	Best response	Details of response
1	WT	73/F	M2	12.2	Normal	80*	NR	—
2	WT	75/M	M2	8.3	Normal	80	NR	—
3	WT	75/M	M6	0.8	Normal	80	NR	—
4	WT	71/M	M1	2.8	Normal	80	NR	—
5	1836 del	72/M	M6	1.9	Normal	80	HR	Delayed PB response (d 104), transfusion independent†
6	WT	69/F	M1	13.8	add(X)(q2)	80	2 × BMR	98% → 24% BM blasts (60 mg), 50% → 21% BM blasts (80 mg)
7	WT	73/M	NA	1.3	Complex	80	NR	—
8	ITD; 30 bp	67/F	M0	3.3	Normal	60	NR	—
9	WT	81/M	M2	9.3	-Y	60	NR	—
10	WT	78/M	M4	19.8	Normal	80	NR	—
11	WT	72/M	M1	3.1	+8	80	NR	—
12	WT	78/F	M4	23.5	-7, +8	60*	NA‡	—
13	WT	80/M	M4	11.4	+11	80	NR	—
14	WT	70/M	NA	3.4	Normal	60	PD	—
15	ITD; 33 bp	74/F	M1	140.7	Normal	60*	HR	Cleared PB blasts (60 mg)
16	WT	82/F	M1	1.2	t(15;21)	60	NA‡	—
17	WT	72/F	NA	1.0	Normal	80	BMR	80% → 30% BM blasts (60 mg), delayed PB response (d 123), transfusion independent†
18	WT	70/F	M1	1.4	inv(8)	80	NR	—
19	D835Y	74/M	M0	42.4	Normal	80*	HR	Cleared PB blasts (60 mg), transfusion independent
20	WT	68/M	M6	1.9	Complex	60	NR	—
21	WT	75/F	M2	1.6	Normal	80	NR	—
22	WT	75/F	M1	6.1	t(8;21)§	80	NR	—
23	WT	73/M	M5	3.3	Normal§	80	BMR	31% → 10% BM blasts (60 mg)
24	WT	73/M	M4	15.1	Normal§	60	PD	—
25	835-837∥	69/F	M4	31.5	Normal	60*	PD	—
26	WT	70/M	M2	1.9	del(9), +11	80	BMR	90% → 45% BM blasts (60 mg)
27	WT	70/F	M4	10.5	+iso(4)×2	60	PD	—
28	WT	80/F	M2	8.0	del(5q)§	80	BMR	22% → 4% BM blasts (60 mg)
29	WT	74/M	M2	7.0	Complex	60	PD	—

WCC indicates white cell count at time of diagnosis (× 10⁹/L); dose, maximum evaluable twice-daily dose of lestaurtinib achieved; NA, not assessed; and —, no notes.

Patients receiving hydroxyurea prior to commencing lestaurtinib.

†

Patients 5 and 17 showed delayed responses with periods of blood-count normalization and transfusion independence lasting 4 and 6 months from days 104 and 123, respectively.

‡

Patients 12 and 16 withdrew early due to toxicity. Clinical responses not evaluable.

Retrospective fluorescent in situ hybridization (FISH) analysis of BM MNCs cryopreserved at presentation.

∥

Novel D835V, I836F, M837P tyrosine kinase domain mutation.³⁸

View Large

This Feature Is Available To Subscribers Only